In Brief: Glaxo Wellcome Zyloprim
Executive Summary
Glaxo Wellcome Zyloprim: Allopurinol sodium eq 500 mg base/vial injection approved May 17 for management of patients with leukemia, lymphoma and solid tumors receiving cancer therapy that causes uric acid level elevations and who cannot tolerate oral Zyloprim therapy. The injectable xanthine oxidase inhibitor was recommended for approval by an FDA advisory committee in March 1993 and became "approvable" in October...